Management Team

Miranda Toledano - CEO

Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/ capital market experience in the biotech sector. Ms. Toledano has served as a Member of the Board of Directors at Entera since 2018, and as Member of the Scientific Advisory Committee since February 2022. In May 2022, she also joined as Entera’s Chief Business Officer and Chief Financial Officer. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (Nasdaq: CMPX). At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX). Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL) and Lipomedix. Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Dr. Hillel Galitzer – COO

Dr. Galitzer has more than ten years of experience in medical research and molecular biology and was mentored by two world renowned researchers in the field of PTH and calcium regulation. He has served as COO since February 2014, and on partial time as Director of Scientific Development since July 2010. Between August 2010 and February 2014 Dr. Galitzer was an analyst and COO for Hadasit Bio Holdings Ltd., a publicly traded company on the TASE and OTC markets. Dr. Galitzer is the co-founder and Chief Operating Officer of Optivasive Inc. He has written numerous publications in tier one peer reviewed articles and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, and his M.B.A. from Bar-Ilan University in Israel.

Dr. Arthur Santora - CMO

Dr. Santora has more than 30 years of experience in the biotech industry. He has spent the majority of his career in the clinical research team at Merck, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax® (alendronate sodium), one of the world's most prescribed osteoporosis treatments. Dr. Santora was closely involved in the clinical development of Merck’s once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position when he retired from Merck in 2017 was as Scientific Associate Vice President of Clinical Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Dr. Santora started his career at the FDA after completing an Endocrinology and Metabolism fellowship at the NIH Clinical Center in Bethesda, MD. He received an M.D. and Ph.D. in biochemistry from Emory University in Atlanta.

Dana Yaacov-Garbeli - CFO

Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience. Ms. Yaacov-Garbeli has served as the Company’s Israel-based Chief Financial Officer since June 2019. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She is an expert in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.